Genentech’s Sigh Of Relief: RIBBON-1 Trial Supports Avastin Use In Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Third study to show progression-free survival in metastatic breast cancer puts the company closer to full approval, and data on new combinations could expand the market.
You may also be interested in...
ASCO IN BRIEF
SATURN fails to find predictive biomarker for Tarceva: Roche/OSI's Phase III SATURN trial of Tarceva may help establish erlotinib as first-line maintenance therapy for non-small cell lung cancer patients who did not progress following first-line treatment with platinum-based chemotherapy, but it failed to establish KRAS mutation status as a predictive biomarker for Tarceva. The trial yielded a significant 41 percent improvement in progression-free survival, the primary endpoint, with a stronger PFS impact in patients with EGFR-positive tumors. But pre-planned biomarker analyses found benefit in both KRAS mutant and wild-type patients, though the effect was stronger in patients with KRAS mutations. "The EGFR immunohistochemistry, EGFR FISH and KRAS mutation status were not strong predictive factors, and selection of patients based on these is not warranted," Roche Clinical Science Leader, Tarceva Ivan Melezinak said. Overall survival data is expected to be ready in the second half of 2009. OSI submitted an sNDA to FDA based on the study in March, and Roche has filed for European approval. Results from the similar ATLAS study were also presented (1"The Pink Sheet" DAILY, Feb. 23, 2009); overall survival from that study, which supports the addition of Tarceva to Avastin after platinum chemo/Avastin therapy, are expected toward the end of the year
ASCO IN BRIEF
SATURN fails to find predictive biomarker for Tarceva: Roche/OSI's Phase III SATURN trial of Tarceva may help establish erlotinib as first-line maintenance therapy for non-small cell lung cancer patients who did not progress following first-line treatment with platinum-based chemotherapy, but it failed to establish KRAS mutation status as a predictive biomarker for Tarceva. The trial yielded a significant 41 percent improvement in progression-free survival, the primary endpoint, with a stronger PFS impact in patients with EGFR-positive tumors. But pre-planned biomarker analyses found benefit in both KRAS mutant and wild-type patients, though the effect was stronger in patients with KRAS mutations. "The EGFR immunohistochemistry, EGFR FISH and KRAS mutation status were not strong predictive factors, and selection of patients based on these is not warranted," Roche Clinical Science Leader, Tarceva Ivan Melezinak said. Overall survival data is expected to be ready in the second half of 2009. OSI submitted an sNDA to FDA based on the study in March, and Roche has filed for European approval. Results from the similar ATLAS study were also presented (1"The Pink Sheet" DAILY, Feb. 23, 2009); overall survival from that study, which supports the addition of Tarceva to Avastin after platinum chemo/Avastin therapy, are expected toward the end of the year
Genentech Mum On Roche Deal As Analysts Guess Price
Third-quarter earnings call features grumbles over lack of transparency.